| scholarly article | Q13442814 |
| P50 | author | Ngozi Erondu | Q94373328 |
| P2093 | author name string | Ann Ginsberg | |
| Elliott Pauli | |||
| Erica Egizi | |||
| Helen Winter | |||
| Daniel Everitt | |||
| Karl Whitney | |||
| P2860 | cites work | 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial | Q39580496 |
| Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects | Q24641829 | ||
| PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release | Q24654913 | ||
| A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis | Q28139874 | ||
| Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models | Q33836720 | ||
| Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients | Q34045233 | ||
| Phase II dose-ranging trial of the early bactericidal activity of PA-824 | Q36018781 | ||
| Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis | Q36538719 | ||
| Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects | Q37333140 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| bioavailability | Q461809 | ||
| P304 | page(s) | 5516-5520 | |
| P577 | publication date | 2013-08-26 | |
| P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
| P1476 | title | Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects | |
| P478 | volume | 57 |
| Q59808748 | A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans |
| Q30251497 | Insights into the pharmacokinetic properties of antitubercular drugs. |
| Q38269581 | Investigational drugs for visceral leishmaniasis |
| Q90387913 | Modeling and Simulation of Pretomanid Pharmacodynamics in Pulmonary Tuberculosis Patients |
| Q52584725 | Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. |
| Q104618374 | Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers |
| Q92575601 | Population Pharmacokinetics of the Antituberculosis Agent Pretomanid |
| Q58606477 | Tumor-Associated Fibronectin Targeted Liposomal Nanoplatform for Cyclophilin A siRNA Delivery and Targeted Malignant Glioblastoma Therapy |
Search more.